Sanjay Mehta, M.D.

And that's a big reason why a lot of the older data was not as good for radiation because of the patient selection criteria. But in the modern era, as we've gotten more and more precise and our side effects have gone down and our cure rates have gone up, now it's pretty much wide open where pretty much anybody who's eligible for surgery would also be eligible for radiation.

And that's a big reason why a lot of the older data was not as good for radiation because of the patient selection criteria. But in the modern era, as we've gotten more and more precise and our side effects have gone down and our cure rates have gone up, now it's pretty much wide open where pretty much anybody who's eligible for surgery would also be eligible for radiation.

So there's not that big of a divergence as there once was.

So there's not that big of a divergence as there once was.

He and I may have another text thread in case our teams meet in the playoffs as well. He's a big Ravens fan, and I'm from Houston, so I'm hoping we get there.

He and I may have another text thread in case our teams meet in the playoffs as well. He's a big Ravens fan, and I'm from Houston, so I'm hoping we get there.

So to answer your last question first, androgen deprivation for high-risk disease is certainly standard of care. Gleason 8 or higher for sure. The Gleason 7s are always a gray zone. And so a 4 plus 3 with high-volume disease typically also do get concurrent and adjuvant androgen suppression along with radiation.

So to answer your last question first, androgen deprivation for high-risk disease is certainly standard of care. Gleason 8 or higher for sure. The Gleason 7s are always a gray zone. And so a 4 plus 3 with high-volume disease typically also do get concurrent and adjuvant androgen suppression along with radiation.

But one of the things that's really changing now is I know Ted talked a lot about with the Decipher score where they can look at the chromosomes of the actual cancer cells and have a much more granular view of exactly are they truly high risk or can you say that this one 3 plus 4 is more like a 3 plus 3. So for a lot of the 3 plus 4s now with the Decipher test, And there's also an AI test.

But one of the things that's really changing now is I know Ted talked a lot about with the Decipher score where they can look at the chromosomes of the actual cancer cells and have a much more granular view of exactly are they truly high risk or can you say that this one 3 plus 4 is more like a 3 plus 3. So for a lot of the 3 plus 4s now with the Decipher test, And there's also an AI test.

I know you had a really interesting discussion with your AI expert, and that wasn't too long ago, called Arterra. And we're using that. That's actually in the NCCN guidelines now, so that Arterra test can help us differentiate between a unfavorable and a favorable intermediate risk patient. I treated my own father not too long ago. He was the first person I did this on.

I know you had a really interesting discussion with your AI expert, and that wasn't too long ago, called Arterra. And we're using that. That's actually in the NCCN guidelines now, so that Arterra test can help us differentiate between a unfavorable and a favorable intermediate risk patient. I treated my own father not too long ago. He was the first person I did this on.

The arteri test is essentially, they just use the actual images of the H&E slides that were already done from the pathologist. And it's interpreted by a machine learning computer that has been trained on hundreds of thousands of prostate images from the old RTOG studies, the 94s, all the stuff that was done back in the 90s.

The arteri test is essentially, they just use the actual images of the H&E slides that were already done from the pathologist. And it's interpreted by a machine learning computer that has been trained on hundreds of thousands of prostate images from the old RTOG studies, the 94s, all the stuff that was done back in the 90s.

And it can now come back and say, okay, very much like decipher, it can say that this is a 3 plus 4, but it's a favorable or an unfavorable person in that subgroup. And so because of that, we can stratify better and actually tailor it to where maybe a 3 plus 4 doesn't need androgen ablation at all.

And it can now come back and say, okay, very much like decipher, it can say that this is a 3 plus 4, but it's a favorable or an unfavorable person in that subgroup. And so because of that, we can stratify better and actually tailor it to where maybe a 3 plus 4 doesn't need androgen ablation at all.

And maybe even some four plus threes, if they come back low enough on the scale, you always have to talk about the side effects and whatnot. But the standard of care was always to give concurrent androgen ablation for intermediate risk. But now we're able to really take some of those people out of the equation with these new studies.

And maybe even some four plus threes, if they come back low enough on the scale, you always have to talk about the side effects and whatnot. But the standard of care was always to give concurrent androgen ablation for intermediate risk. But now we're able to really take some of those people out of the equation with these new studies.

Those are number one and number two. Yeah, lack of incontinence and lack of impotence. But of course, when you have androgen ablation, that clouds things a little bit. But typically, the number one thing we see is patients who don't want to deal with diapers.

Those are number one and number two. Yeah, lack of incontinence and lack of impotence. But of course, when you have androgen ablation, that clouds things a little bit. But typically, the number one thing we see is patients who don't want to deal with diapers.